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Summary Isophosphoramide mustard was synthesized and was found to demonstrate activity essentially
comparable to cyclophosphamide and ifosfamide against L1210 and P388 leukaemia. Lewis lung carcinoma,
mammary adenocarcinoma 16/C, ovarian sarcoma M5076, and colon tumour 6A, in mice and Yoshida ascitic
sarcoma in rats. At doses less than, or equivalent to, the LD1O, isophosphoramide mustard retained high
activity against cyclophosphamide-resistant L1210 and P388 leukaemias, but was less active against
intracerebrally-implanted P388 leukaemia while cyclophosphamide produced a 4 log1o tumour cell reduction. It
was also less active (one log1o lower cell kill) than cyclophosphamide against the B16 melonoma. Metabolism
studies on ifosfamide in mice identified isophosphoramide mustard in blood. In addition, unchanged drug,
carboxyifosfamide, 4-ketoifosfamide, dechloroethyl cyclophosphamide, dechloioethylifosfamide, and
alcoifosfamide were identified. The latter 4 metabolites were also identified in urine from an ifosfamide-
treated dog. In a simulated in vitro pharmacokinetic experiment against L1210 leukaemia in which drugs were
incubated at various concentrations for various times, both 4-hydroxycyclophosphamide and
isophosphoramide mustard exhibited significant cytoxicity at concentration times time values of 100-1000
pg minml-1, while acrolein was significantly cytotoxic at lOug minml'. Treatment of mice with drug
followed by L1210 cells demonstrated a shorter duration of effective levels of cytotoxic activity for
isophosphoramide mustard and phosphoramide mustard in comparison with cyclophosphamide and
ifosfamide. Isophosphoramide mustard and 2-chloroethylamine, a potential hydrolysis product of
isophosphoramide mustard and carboxyifosfamide, were less mutagenic in the standard Ames test than the 2
corresponding metabolites of cyclophosphamide [phosphoramide mustard and bis(2-chloroethyl)amine].
Ifosfamide (IFA) (Brock, 1968), an isomer of the
established clinical anti-tumour and immuno-
suppressive drug cyclophosphamide (CPA) (Arnold
et al., 1958; 1961), has been used in recent years
against many human cancers (Burkert, 1977). Our
earlier studies in mice (Struck, 1976) and dogs (Hill
et al., 1973) included the first report of identification
of isophosphoramide mustard (IPM) as a
metabolite of IFA, and the presence of this
metabolite in plasma of patients treated with IFA
was recently described (Bryant et al., 1980).
Chemotherapy with IFA and CPA is frequently
limited by their urotoxicity, and acrolein, a
common metabolite discovered by Alarcon et al.,
(1972), has been implicated as the causative agent of
this toxicity (Brock et al., 1979; Cox, 1979).
IPM was synthesized and evaluated against a
spectrum of experimental leukaemias and solid
tumours to determine whether it is potentially
responsible for the anti-tumour effect of IFA in vivo.
Materials and methods
Starting materials Phenyl phosphorodichloridate,
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2-chloroethylamine hydrochloride, and triethyl-
amine were purchased from the Aldrich
Chemical Co., Milwaukee, Wis. Platinum oxide was
obtained from Englehard Industries, Newark, N.J.
"4C-IFA (specific activity, 5.6 mCimM-1) labeled in
both 2-chloroethyl groups was obtained from Dr.
Robert R. Engle, National Cancer Institute, Silver
Spring, MD.
Instrumentation Mass spectral analysis was
performed with a Varian MAT Model 311A mass
spectrometer and proton magnetic resonance
(PMR) measurements with a Varian XL-100-15
spectrometer (Varian, Inc., Palo Alto, CA). Infra-red
analysis was performed with Perkin-Elmer Model
521 and 621 spectrophotometers (Perkin-Elmer
Corp., Norwalk, Conn). Melting points were
determined with a Kofler Heizbank apparatus and
are corrected.
Thin-layer chromatography (TLC) TLC was
performed on Analtech (Newark, Del.) silica gel G
plates (250pm thick) in acetone:chloroform (1:3, 2
developments, for chloroform extracts; or 3:1 for
methanol extracts). The plates were activated at
120°C for 1h and stored in a desiccated chamber.
The following Rf values were observed in
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acetone:chloroform (1:3, 2 developments): IFA,
0.40; 4-ketoifosfamide, 0.65; dechloroethyl-
cyclophosphamide and -ifosfamide, 0.13; 4-
hydroxyifosfamide, 0.10; alcoifosfamide, 0.05. The
Rf value of both carboxyifosfamide and IPM, as
their methyl esters, was 0.7 in acetone:chloroform
(3:1). Under these conditions, 0.5pg of these
standards can be detected.
Alkylating activity Thin-layer chromatograms were
sprayed with a 1% solution of 4-(p-
nitrobenzyl)pyridine (NBP, Aldrich Chemical Co.)
in acetone, heated in an oven for 15min at 140°C,
and sprayed with a 3% solution of potassium
hydroxide in methanol. Alkylating components
yielded blue spots.
Anti-tumour evaluation All compounds were
evaluated in murine tumour models in accordance
with protocols established by the National Cancer
Institute (Geran et al., 1972). With the L1210 and
P388 leukeamias, the tumours were maintained in
DBA/2 mice and passaged weekly by the i.p.
transplantation of quantified ascitic leukaemia cells
into healthy 10- to 12-week old mice. For the
chemotherapy trials, 5- to 7-week old hybrid mice
of the CDF1 (BALB/cxDBA/2) strain were used.
Drugs were dissolved in physiological saline and
were administered i.p. 24 or 48 h after implantation
of leukaemia cells. All experiments included a range
of drug dose levels, 10 mice/group, and the
leukaemia inoculum was titrated down to one cell
by dilution, to provide for estimation of tumour cell
doubling time and the calculation of tumour cell
kill (Schabel et al., 1977).
The B16 melanoma, M5076 ovarian tumour, and
Lewis lung carcinoma were maintained in C57BL6
mice (host of origin). For experimentation, B6D2F1
(C57BL/6 x DBA/2) mice were used. The mammary
16/C tumour was maintained in C3H mice and for
experimentation C57BL/6 x C3H mice were used.
All tumours were passaged every 2-3 weeks.
Treatment in all solid tumour experiments was
begun 2-3 days after s.c. implantation of 20-30mg
tumour fragments. All tumours were measured with
calipers twice weekly and the following formula
used to calculate mass: (a x b2)/2, where a
=length(mm) and b =width (mm). Unit density was
assumed. Delays in time for tumours ro reach a
predetermined weighr [test - control (T- C)
values], determined by the difference in treated
group- and control group-median values were used
to estimate cell kill (Schabel et al., 1977).
Colon tumour 06/A was maintained in BALB/c
mice, and the host for chemotherapy was CDF1
(BALB/c x DBA/2) mice. The techniques of
chemotherapy and data analysis have been
presented in detail elsewhere (Corbett et al., 1977;
1979; Schabel et al., 1977).
The Yoshida ascitic sarcoma C was maintained in
8-week-old female Sprague-Dawley rats and
passaged weekly by the transfer of 5 x 106 ascites
cells. The therapy experiments were carried out in
6- to 10-week-old rats implanted i.p. with 1 x 107
cells, with drugs administered i.p. according to exact
body weight 24h after implant. Control and treated
groups were observed for 120 days.
Comparisons of anti-tumour activity were made
at the highest non-toxic dose required to kill 10% of
test animals (LD1o) in a dose-response study. Some
variation in LD10 doses for CPA, IFA,
phosphoramide mustard (PM), and IPM were
observed from experiment to experiment.
Metabolism studies 14C-IFA (450mgkg 1,
0.1pCi/mouse) in saline was administered i.p. to 75
male BDF1 (C57BL x DBA/2) mice (Southern
Animal Farms, Prattville, AL, avg. wt. 21 g), and 3
sets of 25 mice were anaesthetized with carbon
dioxide after 10, 30, and 60min. An incision was
made in the skin over the axilla. The axillary artery
was opened and blood was collected in a syringe as
it flowed onto the s.c. tissue in the axillary space.
Blood was stored on ice until collection for each
time period was complete. Blood samples (vol.
approximately 10ml from each time period and
from 0.2-0.6ml/mouse) were immediately extracted
with chloroform followed by methanol with
diazomethane treatment of the methanol extract as
described previously (Alberts et al., 1978). Under the
conditions of the assay, only 4-hydroxy-ifosfamide
was observed to be unstable, thus accounting for
our failure to detect it in this study. Dog urine was
collected by catheter and frozen on dry ice
immediately upon collection.
Results
Synthesis IPM was synthesized by the following
route:
PhOP(O)C12 +2ClCH2CH2NH2-HCl
j4Et3N
PhOP(O)(NHCH2CH2C1)2
jH2,PtO2
HOP(O)(NHCH2CH2C1)2
Phenyl phosphorodichloridate (21.1 g, 0.1 mole) in
500ml acetone was cooled in an ice bath and
treated in one batch with 2-chloroethylamine
hydrochloride (23.2g, 0.2mole). To the mixture,
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with stirring over 1 h, and the mixture was stirred
16h at room temperature. Filtration removed
triethylamine hydrochloride, and evaporation of the
filtrate in vacuo gave a syrup (12g), mass spectral
analysis of which was satisfactory for the expected
intermediate, phenyl N,N'-bis(2-chloroethyl)-
phosphorodiamidate: m/z 296 [M+, 2CI], m/z 261
[(M-Cl)+, 1 Cl], m/z 247 [(M-CH2Cl)+, 1 Cl],
m/z 218 [(M-CH2CH2Cl)', 1 Cl]. The syrup (2.2g)
in chloroform (20ml) was washed with 10ml each of
N hydrochloric acid, N potassium hydroxide and
water. The chloroform solution was dried over
sodium sulphate, filtered, and evaporated in vacuo,
giving a syrup (1.3g). The syrup in ethanol
(absolute, 20ml) was treated with platinum oxide
catalyst (250mg) and hydrogenated in a Parr
hydrogenation apparatus with shaking for 5h at
room temperature and 50lbs in 2 pressure. The
reaction mixture, which contained a white,
crystalline precipitate, was filtered to collect the
catalyst and precipitate. The filtrate was
concentrated in vacuo to 10ml and filtered to collect a
white, crystalline precipitate (melting point, 137-8°;
230mg after drying in vacuo). The catalyst-
precipitate mixture was extracted with warm
ethanol (2 x 1Oml). The combined washings, after
filtration, were concentrated in vacuo to 10ml and
filtered to collect a white, crystalline precipitate
(melting point, 137-80; 240mg after drying in
vacuo). Analysis of this sample gave the following
data: carbon-hydrogen-nitrogen (CHN) analysis: C,
21.74; H, 5.02; N, 12.81; theory: C, 21.74; H, 5.02; N,
12.67; infrared spectrum (cm-l): 3400, 3300, 2900,
2700, 2540, 2430, 2400, 1570, 1440, 1430, 1400, 1370,
1360, 1335, 1305, 1290, 1260, 1240, 1170, 1130, 1090,
1015, 940, 910, 870, 835, 775, 680, 660, 650, 550,
490, 465, 420, 385, 355, 335; proton magnetic
resonance in dimethyl sulphoxide with tetra-
methylsilane as the internal reference: chemical shift
(ppm) 2.90-3.15 (4H, quintuplet, -NH-CH2-),
3.50-3.65 (4H, triplet, -CH2Cl), 6.50 (3H, broad
singlet, -NH-, -OH); mass spectrum: field
desorption: mass/charge ratio (m/z) 221 (2 Cl,
[molecular ion (M)+1]+); electron impact: m/z 221
(2 Cl, [M + 1]', relative abundance 20), 171 (1 Cl,
[M-CH2Cl]+, relative abundance 100).
Metabolism of IFA to IPM in vivo chloro-
form and methanol extracted all of the
radioactivity from 3 blood samples, taken from
groups of mice administered 14C-IFA. TLC of the
chloroform extracts along with synthetic standards
identified 4-ketoifosfamide, dechloroethyl cyclophos-
phamide (Bakke et al., 1972), dechloroetflvl-
ifosfamide (Norpoth, 1976), alcoifosfamide, and
unchanged drug (Struck, 1976). Identifications were
confirmed by mass spectral analysis of acetone
eluates of appropriate radioactive and NBP-positive
components. The mass spectrum of alcoifosfamide,
which has not been reported previously, gave m/z
278 (2Cl, M+, relative abundance 1) m/z 221 (2 Cl,
[M-CH2CH2CH2OH +2H]+, relative abundance
20), and m/z 200 (1 Cl, [M-NHCH2CH2CI]+,
relative abundance 100).
TLC of the methanol extracts with synthetic
standards IPM and carboxyifosfamide (Hill et al.,
1973) as their methyl esters identified these 2
metabolites in each extract. Carboxyifosfamide,
which was readily detectable by mass spectral
analysis at 10 and 30 min, was barely detectable
after 60min. Mass spectral analysis indicated that
IPM increased from 10-30min and declined from
30-60min but not as rapidly as carboxyifosfamide.
A chloroform extract of 0-12h urine from a
beagle dog given 20mgkg - of 14C-IFA was
separated by TLC in chloroform:methanol (95:5).
Mass spectral analysis of a methanol eluate of a
radioactive, alkylating band of Rf 0.1 identified 4-
ketoifosfamide (Hill et al., 1973), alcoifosfamide and
the 2 monodechloroethylated isomers of ifosfamide
(Norpoth, 1976). As reported previously, IFA and
carboxyifosfamide were also identified in dog urine
(Hill et al., 1973).
These results, coupled with earlier studies by us
(Hill et al., 1973) and others (Bryant et al., 1980;
Hohorst, 1977; Norpoth, 1976, Takamezawa et al.,
1974) in experimental animals and humans are
consistent with the metabolic pathway shown in the
Figure 1.
Antitumour activity Table I shows the effect of
IPM in mice implanted with 105 or 106 L1210 cells
(Day 1 treatment) and of IPM, IFA, PM and CPA
against 107 cells with drug treatment on day 2,
when the cell burden was approximately 108 cells.
The results indicate that IPM as a cytotoxic agent
in vivo is comparable to both CPA and IFA.
Evaluation of various combinations of IPM given
simultaneously with CPA to mice with advanced
L1210 leukaemia (data not shown) indicated no
clear advantage for combination treatment based on
total tumour cell kill, although median survival
time was increased somewhat (23.5 vs. 17 days). As
shown in Table II, IPM retained its activity against
a line of L1210 leukaemia that was partially
resistant to CPA and IFA.
IPM was active against CPA-sensitive P388
leukaemia, and retained most of its activity against
a line of P388 leukaemia that was partially resistant
to CPA and IFA (Table III). Although there were
fewer survivors in the IPM-treated group bearing
the sensitive line, total cell kill was equivalent for
IPM, CPA, and IFA. Comparison of the
antitumour effect of CPA, IFA, PM, and IPM18 R.F. STRUCK et al.
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Figure 1 Metabolism of Ifosfamide.
Table I Single- and multi-dose administration of isophosphoramide mustard and phosphoramide mustard
against L1210 leukaemia (optimal response at <LDI0 dose, from dose-response study)
Treatment- i.p. Therapeutic response
Net log1o
Implant 45-Day Percent ILS reduction in
Expt. (No. of Dosaget survivors (Dying mice tumour burden
No. cells) Agent Schedule (mg/kg) Itotal only) after therapy,
1 105 Isophosphoramide Day 1,
mustard Single dose 100 6/10 118 6
2 106 Isophosphoramide Day 1,
mustard Single dose 100 5/10 114 6
3 107 Cyclophosphamide Day 2,
Single dose 300 1/10 166 8
Ifosfamide Day 2,
Single dose 450 0/10 116 6
Phosphoramide Day 2,
mustard Single dose 140 0/10 66 3
Day 2,
Q5min x 7 35 1/10 116 6
Isophosphoramide Day 2,
mustard Single dose 200 0/10 140 8
Day 2,
Q5min x 7 30 0/10 116 6
*Implant: i.p.; in male CDF1 mice.
tHighest non-toxic dose (LD10 or less) in a range ofdoses.
tNet loglo reduction in viable tumour cell population after last treatment as compared to the start of therapy;
e.g., a 6-log10 reduction=99.9999% decrease in viable leukaemia cells (Schabel et al., 1977).ANTI-TUMOUR ACTIVITY OF ISOPHOSPHORAMIDE MUSTARD 19
Table II Activity of isophosphoramide mustard against L1210/0 and L1210/CPA leukaemias (Optimal response at
,<LD1o dose, from dose-response study)
L1210/0t L1210/CPAt
Tumour burden at start of Tumour burden at start of
Rx=8.5 x I07 cells Rx=6.0 x I07 cells
Net log10 Net log,0
Day 60 % ILS reduction in Day 60 % ILS reduction in
Dosage* survivors (dying mice tumour burden survivors (dying mice tumour burden
Agent (mgkg-1) Itotal only) after therapy$ Itotal only) after therapy:
Cyclophosphamide 200 0/10 + 107 7 0/10 +57 4
Ifosfamide 431 0/10 +185 8 0/10 +85 5
289 0/9 +114 8 0/10 +57 4
Isophosphoramide
mustard 100 0/10 + 128 8 1/10 + 114 7
*Treatment: i.p.; day 2 only; highest non-toxic dose (LD10 or less) in a range of doses.
tlmplant: i.p.; 106 cells, in male CDF1 mice.
ISee footnote , Table I.
Table III Activity of isophosphoramide mustard against P388/0 and P388/CPA leukaemias (Optimal response at
, LD1o dose, from dose-response study)
P388/Ot P388/CPAt
Tumour burden at start of Tumour burden at start of
Rx= 4.4 x 106 cells Rx= 4.6 x 106 cells
Net log1o Net log1o
Day 60 % ILS reduction in Day 60 % ILS reduction in
Dosage* survivors (dying mice tumour burden survivors (dying mice tumour burden
Agent (mgkg-1) /total only) after therapy: /total only) after therapy$
Cyclophosphamide 265 7/10 +280 7 0/10 +35 3
175 4/10 +130 7 0/10 +35 3
Ifosfamide 538 7/10 +210 7 0/10 +42 4
431 7/10 +130 7 0/10 +39 4
Isophosphoramide 125 0/9 + 100 6 0/10 +71 7
mustard 100 1/10 +140 7 0/10 +85 7
*Treatment: i.p.; day 1 only; highest non-toxic dose (LD1o or less) in a range of doses.
tImplant: i.p.; 106 cells, in female CDF1 mice.
tSee footnote T, Table I.
against intracerebrally (i.c.) implanted P388 cells
demonstrated that IPM was inactive while CPA,
IFA, and PM produced a 4, 3, and 1 log1o cell
reduction, respectively (Table IV).
Comparison of the response of Lewis lung
carcinoma to IPM, CPA, IFA, and PM gave the
results shown in Table V. Responses were essentially
equivalent to all the drugs except PM, which was
much less active on both single and multiple dose
schedules. Combination of CPA (100mgkg-1) with
either single dose treatment of IPM (100mgkg-1) or
multiple dose treatment with PM (30mgkg-1 dose,
every (q) 5minx7) resulted in 9/9 or 6/9 tumour-
free survivors, respectively. These responses were
equivalent to that given by a single dose of CPA
(200mg/kg), which gave 9/10 survivors.
Responses of mammary adenocarcinoma 16/C s.c.
to IPM and CPA are compared in Table VI. The
results demonstrate that IPM is at least as active as
CPA against this highly metastatic murine tumour.
Comparison of the activity of IPM with that of
cyclophosphamide, IFA, and PM against B1620 R.F. STRUCK et al.
Table IV Activity ofisophosphoramide mustard against intracerebrally-implanted P388 leukaemia*
(Optimal response at <LD10 dose, from dose-response studies)
Net log10o
Day 45 % ILS reduction in
Dosage survivors (dying mice tumour burden
Agent Schedule (mgkg-Idose) Itotal only) after therapy
Cyclophosphamide Day 2, 300 0/10 +65 4
Single dose 200 0/10 +46 3
Ifosphamide Day 2, 450 0/10 +38 3
Single dose 300 0/10 +19 1
Phosphoramide Day 2, 50 0/10 +15 1
mustard Q30min x 3 33 0/8 +3 <1
Isophosphoramide Day 2, 100 0/10 0 0
mustard Single dose
Day 2, 50 0/10 +3 <1
Q30min x 3 33 1/10 0 0
*Implant: i.c.; 103 cells, in female CDF1 mice.
tSee footnote $, Table I.
Table V Response of Lewis lung carcinoma to isophosphoramide mustard implant size: 20-30mg;
implant site: s.c.; drug treatment: i.p.
Highest
non-toxic Log
dosage Tumour-free kill
Agent Schedule (mgkg- I/dose) survivors T- C*t %ILSt total§
Cyclophosphamide Day 2,
Single dose 200 5/10 27. 68 >6.8
Ifosfamide Day 2,
Single dose 300 7/10 18 55 >4.5
Phosphoramide Day 2,
mustard Single dose 200 0/10 4.9 15 1.2
Day 2,
QSmin x 7 30 0/10 6.1 17 1.5
Isophosphoramide Day 2,
mustard Single dose 100 6/10 8 4 34 >2.1
*Tumour growth delay (T-C), where T=median time (days) required for the treatment-group
tumours and C, the control-group tumours (median of 10 each) to reach a predetermined weight
(750mg). Tumour-free survivors were excluded from these calculations.
tControl: Median day of death=29; time for median tumour to reach 750mg= 10.4 days; there
were no tumour-free survivors among the 30 control mice.
tlncrease in life span, excluding survivors.
§The Log1o cell kill (total) was calculated from the following formula: Log kill = T-C
value/(3.32 Td). Where Td is the tumour volume-doubling time measured from a best fit straight line
of the control-group tumours in exponential growth (100-400mg range). Td= 1.2 for Lewis tumour
in this experiment.ANTI-TUMOUR ACTIVITY OF ISOPHOSPHORAMIDE MUSTARD 21
Table VI Response of early stage mammary adenocarcinoma 16/C to isophosphoramide
mustard implant size: 40-50mg: implant site: s.c., drug treatment: i.p.
Highest
non-toxic Schedule
dosage (dayspost Log10 Kill:
Agent (mgkg- IIdose) implant) %ILS T-C*t total Cures
Cyclophosphamide 59 3,7,11,15 70 12 2 0/10
Isophosphoramide
mustard 59 3,7,11,15 72 15 2.5 0/10
*See footnote *, Table V.
tControl: Median day of death=29; time for median tumour to reach 750mg= 15 days; there
were no tumour-free survivors among the 20 control mice.
$The Log1o cell kill (total) was calculated from the following formula: Log kill= T-C
value/(3.32) (Td). Where Td is the tumour volume-doubling time measured from a best fit straight
line of the control-group tumours in exponential growth (100-400mg range). Td= 1.8 for 16/C in
this experiment.
Table VII A comparison of the response of s.c. B16 melanoma and ovarian sarcoma
M5076 to cyclophosphamide, isophosphoramide mustard, phosphoramide mustard, and
ifosfamide
B16 melanoma Ovarian sarcoma
Rx Dosage T-C* T- C*
Agent schedule (mgkg-') (days) %ILS (days) %ILS
Cyclophosphamide Day 2,
Single dose 300 16 78 19 39
Isophosphoramide Day 2,
mustard Single dose 150 7 62 15 20
Phosphoramide Day 2,
mustard q5min x 7 30 x 7 2 64 11 17
Ifosfamide Day 2,
Single dose 460 12 50 14 20
*See footnote with Table V. Predetermined weight was 750mg for B16 melanoma and
750mg for ovarian sarcoma.
melanoma and ovarian sarcoma M5076 gave the
results shown in Table VII. CPA and IFA resulted in
-3 log net cell kill, and IPM gave a 2 log net cell
kill against B16 melanoma, while PM caused only a
marginal tumour delay. Against the ovarian tumour,
all but PM gave - 2 log net cell kill. PM gave a 1
log net cell kill against this tumour on a multiple-
dose schedule.
IPM, PM, IFA, and CPA showed only limited
activity against s.c. growing, advanced-stage (100-
400mg size) colon adenocarcinoma 06/A in CDF1
mice. At the maximum tolerated dosage levels
(LD1o or less), q7 day (d) x 3 i.v. treatment (CPA-63
mgkg 1/dose; PM, 63mgkg-1/dose; IPM,
100mgkg- /dose; IFA, 160mgkg-'/dose), there
were no partial or complete tumour regressions.
IPM was, however, at least as active as CPA based
on tumour growth delay to 1250mg (T-C) and
increase in life span over that of untreated controls
(ILS) (IPM= 14 day T-C, 116% ILS compared
with CPA=6.3 day T-C, 58% ILS).
Evaluation of IPM was performed against a
single rat tumour, Yoshida ascitic sarcoma, the
signal tumour used to select candidate oxaza-
phosphorines for further investigations (Arnold et
al., 1961). Results areshowninTable VIII andindicate
no clear differences in antitumour activity for
single-dose treatment with IPM, CPA, IFA or PM
or multiple-dose treatment with the latter.
Confirmation of the activity of IPM was obtained
in the National Cancer Institute's experimental
tumour test panel. IPM passed Decision Network 222 R.F. STRUCK et al.
for L1210 and P388 leukaemias, Lewis lung
carcinoma, B16 melanoma, colon tumour 38, and
mammary tumour CD8F1. IPM was inactive
against a lung tumour xenograft and a mammary
tumour xenograft.
Pharmacokinetics and pharmacodynamics of L1210
leukaemia cell killing In order to determine what
range of values of the pharmacokinetic parameter,
concentration times time (C x T), is efficacious for
appreciable L1210 leukaemia cell kill, IPM, 4-
hydroxycyclophosphamide (the activated metabolite
of CPA), PM, and acrolein, a toxic metabolite of
CPA and IFA (Alarcon et al., 1972), were incubated
with L1210 cells at 35°C in a shaker water bath at
various concentrations for various times. Cell kill in
vitro was determined by bioassay in vivo by
implanting aliquots of the cell/drug suspension in
female CDF1 mice and observing for life span
(Schabel et al., 1977). Several times were compared
with those of control mice receiving titrated
numbers of cells from a cell suspension incubated
without drug, and the results are shown in Table IX.
Acrolein was the most cytotoxic agent, causing a 4-
Table VIII Effect of isophosphoramide mustard, phosphoramide mustard,
cyclophosphamide and ifosfamide against Yoshida sarcoma in rats. Implant 107
cells i.p., 80% take rate; drug treatment day 1; duration of expt.= 120 days
Percent Percent ILS*
Dose day 120 (dying
Agent (mgkg-1) Schedule survivors animals only)
Isophosphoramide 100 Single dose 60 514
mustard 75 80 492
Phosphoramide 140 Single dose 90 71
mustard 105 90 0
70 90 114
20 q5min x 7 90 828
15 100 1
Cyclophosphamide 225t Single dose 20 71
150 90 -58
Ifosfamide 225 Single dose 100
150 90 -58
*Median survival time among the 16/20 control animals that dies was 7 days.
tToxic dose.
Table IX L1210 leukaemia cell kill in vitro with isophosphoramide mustard
phosphoramide mustard, 4-hydroxycyclophosphamide and acrolein
Log,0cell kill
Conc. Exposure
(pgml-1) time(min) IPM PM HOCPA Acrolein g minml-'
0.1 1 <1 <1 <1 <1
1 <1 <1 <1 4
10 I <1 <1 <1 4
100 1 3 1 5 >7 102
0.1 10 <1 <1 <1 1
1 10 <1I <1 1 1
10 10 <1 <1 1 7
100 10 6 3 7 >7 103
0.1 100 <1 <1 <1 <1
I 100 <1 <1 <1 <1
10 100 5 2 6 >7 103
100 100 >7 7 >7 >7 104
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log reduction at a C x T value of only
10pg mminml-'. Both 4-hydroxycyclophosphamide
and IPM exhibited significant cytotoxicity at
100pg minml-1 at high concentration and short-
to-moderate exposure time, and at
1000ug minml-' at high concentration and
moderate exposure time, as well as at moderate
concentration and long exposure time.
The duration of therapeutically-effective blood
levels of CPA, IFA, PM, and IPM was determined
by treating female CDF1 mice with drug (i.p., LD10
dose) and implanting various groups with 107
L1210 cells i.p. 10, 20, 30, or 40 min later. The
results indicated that IPM (200mgkg-') was
capable of killing 6 log10 units of cells for 20 min
compared with 30 min for IFA (450mgkg- ).
Comparable effectiveness for PM (210mgkg-1) and
CPA (300mgkg- ) was 25 min and 40 min,
respectively.
Mutagenic activity IPM and 2-chloroethylamine, a
potential hydrolytic decomposition product of both
IPM and carboxyifosfamide in vivo, were compared
in the Ames mutagenicity test (Ames et al., 1975)
with PM and bis(2-chloroethyl)amine, products of
metabolism or hydrolytic degradation of CPA or its
metabolites (Jardine et al., 1978). The results (data
not presented) indicate greater mutagenic activity
for these alkylating metabolites of CPA [PM and
bis(2-chloroethyl)amine] than for those of IFA
[IPM and 2-chloroethylamine].
Discussion
IPM was synthesized in satisfactory yield by
reaction of phenyl phosphorodichloridate with 2-
chloroethylamine followed by catalytic
hydrogenolysis of the phenyl group. Although the
synthesis of IPM has not been described previously,
it was prepared in 1968 by Brock & Arnold (private
communication), and several reports of its chemical
and toxicological properties were reported
previously (Brock & Hohorst, 1977; Brock et al.,
1979; Hohorst, 1977; Rauen & Schriewer, 1971).
Investigation of the metabolism of IFA in
experimental animals and in humans has
established the metabolic pathway shown in Figure
1. As expected, no major qualitative differences in
metabolism of IFA and CPA were observed. The
isonieric structure of IFA results in the production
of N-dechloroethylifosfamide, a metabolite identified
by Norpoth et al. (1976) in humans, by
Takamizawa et al. (1974) in rabbits, and by us
(Struck, 1976) in mice and dogs.
IPM is an effective agent against several murine
leukaemias and solid tumours, including leukaemias
L1210 and P388 that are partially resistant to CPA
and IFA. As well as PM, it is also active against
Yoshida ascitic sarcoma in rats. This is in contrast
to results of Brock & Hohorst (1977), who reported
low activity for PM but high relative activity for
CPA and its 4-hydroxy derivative against this
tumour. It was closely comparable in efficacy to
CPA and IFA at optimum doses for each of these
agents, against every tumour except i.c. implanted
P388 leukaemia. The relative inactivity of IPM and
PM against the latter, in contrast to the activity
demonstrated by IFA and CPA, suggests a possible
role for their hydroxylated metabolites as transport
forms against this tumour (Brock & Hohorst, 1977;
Colvin et al., 1976, Cox et al., 1975, Domeyer &
Sladek, 1980). The comparable activity of IPM and
CPA against 4 of the tumours described previously
was confirmed by the National Cancer Institute,
and, in addition, IPM was shown to be active
against mouse colon tumour 38.
Conclusive data have not yet been obtained to
permit identification of the metabolite(s) of CPA
and IFA responsible for the cytotoxic action against
tumour cells. Brock & Hohorst (1977) insist that the
selectivity for tumour toxicity resides exclusively
with 4-hydroxy CPA and 4-hydroxy-IFA (or the
isomeric aldophosphamide and aldoifosfamide).
Others (Colvin et al., 1976; Cox et al., 1975;
Domeyer & Sladek, 1980: Hilton et al., 1981;
Sladek, 1977; Sladek et al., 1981; Sladek & Powers,
1980) are totally or partially in agreement with this
view and suggest that the hydroxylated metabolites
are at least important extracellular determinants of
antitumour activity. In contrast, some (Friedman et
al., 1976; Struck et al., 1975) have suggested that the
total or dominant cytotoxicity is controlled by
extracellular PM and IPM, a view consistent with
the high, CPA- and IFA-comparable, antitumour
activity reported herein.
Because of certain observations on DNA cross-
linking (Hilton et al., 1981) and cellular transport
(Lenssen & Hohorst, 1979), it could be suggested
that the mechanisms of action of extracellular PM
and of 4-hydroxycyclophosphamide are different.
The superiority of 4-hydroxycyclophosphamide (or
its precursor 4-hydroperoxycyclophosphamide) to
PM and IPM in vitro has been observed in most
evaluations (Brock & Hohorst, 1977; Hilton et al.,
1981; Sladek & Powers, 1980), including our own
(Table VIII), whereas in vivo the differences in many
evaluations (Friedman et al., 1976; Ramonas et al.,
1981) but not all (Brock & Hohorst, 1977) are less
pronounced or even disappear, particularly with
IPM as shown in the present work. Is the reason
for these differences possibly based on
pharmacokinetic properties, as our results on24 R.F. STRUCK et al.
duration of optimum cell killing factor(s) intimate;
is it a function of cell uptake, or is it that
extracellular 4-hydroxycyclophosphamide and PM
and IPM are acting by different mechanisms, such
as, for example, DNA cross-linking by 4-
hydroxycyclophosphamide vs. membrane alteration
and/or non-DNA alkylation by PM and IPM?
Brock & Hohorst (1977) discount any major
contribution to selectivity in vivo by selective
deactivation by normal cells as proposed primarily
by Domeyer & Sladek (1980) and Cox et al. (1975)
or by pharmacokinetic properties as we have done.
Data presented herein (Tables I-VIII) indicate
comparable selectivity for tumour toxicity in vivo
for IPM, CPA, and IFA at comparable host
toxicity (LD10). The extensive data of Friedman, et
al. (1976), in which PM was compared with CPA
against 25 experimental tumours, demonstrated that
PM was of comparable or superior activity against
18 of them; these data, coupled with those included
herein, clearly demonstrate that extracellularly-
delivered PM and IPM are effective agents, in
many cases with anti-tumour activity and selectivity
in vivo comparable to CPA and IFA and their 4-
hydroxy and 4-hydroperoxy derivatives. Because
these data (Friedman et al., 1976, and those
reported herein) can essentially account for the anti-
tumour activity of the parent drugs in vivo, it seems
reasonable to assume that PM and IPM, delivered
to tumour cells by circulation, contribute
significantly, if not dominantly or exclusively in
some cases, to the observed activity of the parent
drugs and the primary metabolites. Their anti-
tumour effect in vivo suggests that either they
participate directly in tumour cytotoxicity as
extracellulary-delivered metabolites of their parent
drugs, or that they are acting by a mechanism
different from that of the parent drugs and primary
metabolites.
The mutagenicity of IPM and a potential
hydrolytic product, 2-chloroethylamine, was found
to be less than that of PM and its hydrolytic
product, bis(2-chloroethyl)amine. These results
suggest reduced likelihood of mutagenic
transformation after treatment with IFA or IPM in
comparison with CPA or PM.
Haemorrhagic cystitis frequently results from
treatment of patients with CPA and IFA (Morgan
et al., 1981; Scheef et al., 1979), and this toxic effect
has been attributed to the metabolite acrolein
(Brock et al., 1979; Cox, 1979). 4-Hydroxycyclo-
phosphamide and 4-hydroxyifosfamide and the
corresponding hydroperoxy derivatives similarly
yield acrolein upon decomposition. An advantage of
PM and IPM is their inability to generate this toxic
metabolite, although various methods have been
reported (Morgan et al., 1981; Scheef, et al., 1979) to
control acrolein toxicity. Direct instillation of the
phosphorodiamidic acids into bladders of
experimental animals (Brock et al., 1979)
demonstrated the absence of generation of
urotoxicity in comparison with acrolein. Acrolein
has also been shown to cause denaturation of
hepatic microsomal cytochrome P-450 (Marinello et
al., 1978) and to be embryotoxic in rabbits
(Claussen et al., 1980).
IPM is an active alkylating agent and, like PM
(Colvin et al., 1976; Struck et al., 1975), requires no
additional activation. As such, variability in
activation, which is possible after administration of
parent drug, is eliminated. Chemically, IPM appears
to be more resistant to hydrolytic deactivation than
PM. Brock & Hohorst (1977) and Hohorst (1977
reported a hydrolysis half-life of both 840min and
2.6h for IPM, compared to 48min, 180min, and
542min for PM, 4-hydroxycyclo phosphamide, and
4-hydroxyifosfamide, respectively, in 0.07 M
phosphate buffer at 37°C.
Precise quantitative data have not yet been
obtained for the pharmacokinetics of IPM, but our
results demonstrate faster clearance of optimum
levels of L1210 cell killing factor(s) than occurs with
CPA and IFA. This property could be
disadvantageous in that tumour cell exposure to the
cytotoxic agent is less than for parent drug, thus
possibly requiring a divided-dose schedule for
optimum response against some tumours. Faster
clearance could also be advantageous in that
general systemic exposure to the alkylating agent
would be reduced, possibly resulting in less toxicity
than that caused by parent drug.
This investigation was supported by Grant Number CA
26632 from the National Cancer Institute, NIH, DHHS.
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